Analysis of Proteomic Biomarkers for Acute Interstitial Lung Disease (ILD) in Gefitinib-Treated Japanese Non-Small Cell Lung Cancer (NSCLC) Patients

被引：0
|
作者：
Nyberg, Fredrik [1 ,2 ]
Ogiwara, Atsushi [3 ,4 ]
Harbron, Chris G. [5 ]
Kawakami, Takao [3 ,4 ,6 ]
Komatsu, Yasuhiko [3 ,4 ]
Nishimura, Toshihide [3 ,4 ,6 ]
Marko-Varga, Gyorgy [7 ]
机构：
[1] AstraZeneca R&D, Epidemiol, Molndal, Sweden
[2] Karolinska Inst, Inst Env Med, Stockholm, Sweden
[3] Med ProteoScope Co Ltd, R&D Div, Tokyo, Japan
[4] Yokohama City Uni, Adv Med Res Ctr, Yokohama, Kanagawa, Japan
[5] AstraZeneca R&D, Discovery Stat, Alderley Pk, Cheshire, England
[6] Tokyo Med Uni, Dep Surg 1, Tokyo, Japan
[7] Lund Uni, Div Clin Prot Sci & Imaging, Biomed Ctr, Lund, Sweden
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2010年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
262
引用
收藏
页码：S112 / S113
页数：2
相关论文
共 50 条
  • [41] Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors for fatal outcome.
    Kato, Terufumi
    Sakai, Fumikazu
    Baba, Tomohisa
    Kusumoto, Masahiko
    Kenmotsu, Hirotsugu
    Sugiura, Hiroaki
    Tominaga, Junya
    Oikado, Katsunori
    Sata, Masafumi
    Endo, Masahiro
    Yanagawa, Noriyo
    Sasaki, Shinichi
    Iwasawa, Tae
    Saito, Yoshinobu
    Fujiwara, Yutaka
    Ohe, Yuichiro
    Ito, Yoshihiko
    Tahara, Yasuhiro
    Kuwano, Kazuyoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer
    Sata, Masafumi
    Sasaki, Shinichi
    Oikado, Katsunori
    Saito, Yoshinobu
    Tominaga, Junya
    Sakai, Fumikazu
    Kato, Terufumi
    Iwasawa, Tae
    Kenmotsu, Hirotsugu
    Kusumoto, Masahiko
    Baba, Tomohisa
    Endo, Masahiro
    Fujiwara, Yutaka
    Sugiura, Hiroaki
    Yanagawa, Noriyo
    Ito, Yoshihiko
    Sakamoto, Takahiko
    Ohe, Yuichiro
    Kuwano, Kazuyoshi
    CANCER SCIENCE, 2021, 112 (04) : 1506 - 1513
  • [43] Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer
    Na, Im Il
    Choe, Du Hwan
    Kim, Cheol Hyeon
    Koh, Jae Soo
    Ryoo, Baek-Yeol
    Lee, Jae Cheol
    Yang, Sung Hyun
    LUNG CANCER, 2010, 68 (02) : 295 - 298
  • [44] Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease
    Yamaguchi, Teppei
    Shimizu, Junichi
    Shigematsu, Fumie
    Watanabe, Naohiro
    Hasegawa, Takaaki
    Horio, Yoshitsugu
    Inaba, Yoshitaka
    Fujiwara, Yutaka
    JOURNAL OF THORACIC DISEASE, 2024, 16 (05) : 3371 - 3380
  • [45] Impact of Interstitial Lung Disease on Survival for Patients with Non-small Cell Lung Cancer
    Miyazaki, Kunihiko
    Satoh, Hiroaki
    Kurishima, Koichi
    Nakamura, Ryota
    Ishikawa, Hiroichi
    Kagohashi, Katsunori
    Ohara, Gen
    Hizawa, Nobuyuki
    ANTICANCER RESEARCH, 2009, 29 (07) : 2671 - 2674
  • [46] Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
    Kato M.
    Shukuya T.
    Takahashi F.
    Mori K.
    Suina K.
    Asao T.
    Kanemaru R.
    Honma Y.
    Muraki K.
    Sugano K.
    Shibayama R.
    Koyama R.
    Shimada N.
    Takahashi K.
    BMC Cancer, 14 (1)
  • [47] 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
    Pallis, A. G.
    Voutsina, A.
    Kalikaki, Ar
    Souglakos, J.
    Briasoulis, E.
    Murray, S.
    Koutsopoulos, A.
    Tripaki, M.
    Stathopoulos, E.
    Mavroudis, D.
    Georgoulias, V.
    BRITISH JOURNAL OF CANCER, 2007, 97 (11) : 1560 - 1566
  • [48] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [49] T cell immunity in interstitial lung disease with non-small cell lung cancer patients
    Isono, Tomomi
    Iwahori, Kota
    Yanagawa, Masahiro
    Yamamoto, Yoko
    Tone, Mari
    Haruna, Miya
    Hirata, Michinari
    Fukui, Eriko
    Kimura, Toru
    Kanou, Takashi
    Ose, Naoko
    Funaki, Soichiro
    Takeda, Yoshito
    Morii, Eiichi
    Kumanogoh, Atsushi
    Shintani, Yasushi
    Wada, Hisashi
    LUNG CANCER, 2023, 182
  • [50] Independent review of fatal interstitial lung disease (ILD) in TRIBUTE:: paclitaxel plus carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC).
    Gandara, D. R.
    Yoneda, K.
    Shelton, D.
    Beckett, L. A.
    Ramies, D. A.
    Bloss, J.
    Herbst, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 381S - 381S
12345